BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 29278878)

  • 1. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.
    Ricco G; Cavallone D; Cosma C; Caviglia GP; Oliveri F; Biasiolo A; Abate ML; Plebani M; Smedile A; Bonino F; Pontisso P; Brunetto MR
    Cancer Biomark; 2018 Feb; 21(3):603-612. PubMed ID: 29278878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
    Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
    World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
    Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
    Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
    Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
    Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.
    Wang Q; Chen Q; Zhang X; Lu XL; Du Q; Zhu T; Zhang GY; Wang DS; Fan QM
    World J Gastroenterol; 2019 Sep; 25(36):5515-5529. PubMed ID: 31576097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma.
    Wang G; Lu X; Du Q; Zhang G; Wang D; Wang Q; Guo X
    Sci Rep; 2020 Aug; 10(1):13519. PubMed ID: 32782270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
    World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis.
    Xing H; Zheng YJ; Han J; Zhang H; Li ZL; Lau WY; Shen F; Yang T
    Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):487-495. PubMed ID: 30257796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
    Abdel-Razik A; Elhelaly R; Elzehery R; El-Diasty A; Abed S; Elhammady D; Tawfik A
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):599-605. PubMed ID: 26741637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma.
    Gad A; Tanaka E; Matsumoto A; Wahab MA; Serwah Ael-H; Attia F; Ali K; Hassouba H; el-Deeb Ael-R; Ichijyo T; Umemura T; Muto H; Yoshizawa K; Kiyosawa K
    World J Gastroenterol; 2005 Nov; 11(42):6607-12. PubMed ID: 16425352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yoon YJ; Han KH; Kim DY
    Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
    Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
    Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B.
    Yang T; Xing H; Wang G; Wang N; Liu M; Yan C; Li H; Wei L; Li S; Fan Z; Shi M; Chen W; Cai S; Pawlik TM; Soh A; Beshiri A; Lau WY; Wu M; Zheng Y; Shen F
    Clin Chem; 2019 Dec; 65(12):1543-1553. PubMed ID: 31672853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
    Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
    Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
    Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
    J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.